Impact of KAFTRIO on kidney health in cystic fibrosis patients
Renal Impact of KAFTRIO in Mucoviscidose Population
This study is testing how the cystic fibrosis treatment KAFTRIO affects kidney health in adults with the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Pierre-Bénite) |
| Trial ID | NCT06197490 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the renal effects of KAFTRIO, a triple modulator therapy for cystic fibrosis, in adult patients. It will assess various parameters such as plasma and urinary metrics, kidney function, and metabolic changes related to urolithiasis before and after the initiation of treatment. Data will be collected at the start of therapy and during follow-up to monitor any changes in renal health and related factors.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with cystic fibrosis who are eligible for KAFTRIO treatment.
Not a fit: Patients who may not benefit include those under 18 years old, on dialysis, pregnant, or those with contraindications to KAFTRIO.
Why it matters
Potential benefit: If successful, this study could provide insights into the renal safety and efficacy of KAFTRIO in cystic fibrosis patients, potentially improving patient management.
How similar studies have performed: While this specific approach is novel, previous studies on KAFTRIO have shown promising results in improving cystic fibrosis symptoms, suggesting potential for positive outcomes in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with cystic fibrosis * More than 18 years old * Eligible for KAFTRIO Exclusion Criteria: * KAFTRIO contraindication * Patient less than 18 years old * Dialysis patient * Pregnant woman * Greffed patient * Patient opposition to data collection
Where this trial is running
Pierre-Bénite
- Centre Hospitalier Lyon Sud — Pierre-Bénite, France (Recruiting)
Study contacts
- Principal investigator: Etienne NOVEL-CATIN, MD — Hospices Civils de Lyon
- Study coordinator: Etienne NOVEL CATIN
- Email: etienne.novel-catin@chu-lyon.fr
- Phone: 04.72.67.87.37
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.